SPRY — ARS Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $737.31m
- $588.70m
- $84.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.45 | ||
| Price to Tang. Book | 7.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -62.2% | ||
| Return on Equity | -92.33% | ||
| Operating Margin | -212.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 1.32 | 0.03 | 89.15 | 84.28 | 157.45 | 299.71 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Directors
- Peter Thompson CHM (61)
- Valerie Odegard PRE (43)
- Laura Shawver CEO (63)
- Jonathan Piazza CFO (45)
- Naomi Hunder OTH (51)
- Vickie Capps IND (59)
- Robert Hershberg IND (57)
- Saqib Islam IND (51)
- Maria Koehler IND (64)
- Andrew Powell IND (63)
- Jonathan Root IND (61)
- Thilo Schroeder IND (39)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- January 4th, 2016
- Public Since
- December 4th, 2020
- No. of Shareholders
- 13
- No. of Employees
- 158
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 99,300,658
- Address
- 11682 El Camino Real, Suite 300, SAN DIEGO, 92130
- Web
- https://ars-pharma.com/
- Phone
- +1 8587719307
- Contact
- Justin Chakma
- Auditors
- Ernst & Young LLP
Upcoming Events for SPRY
ARS Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2026 ARS Pharmaceuticals Inc Earnings Release
Q3 2026 ARS Pharmaceuticals Inc Earnings Release
Similar to SPRY
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the ARS Pharmaceuticals share price?
As of Today at 19:19 UTC, shares in ARS Pharmaceuticals are trading at $7.43. This share price information is delayed by 15 minutes.
How has the ARS Pharmaceuticals share price performed this year?
Shares in ARS Pharmaceuticals last closed at $7.43 and the price had moved by -39.11% over the past 365 days. In terms of relative price strength the ARS Pharmaceuticals share price has underperformed the S&P500 Index by -51.03% over the past year.
What are the analyst and broker recommendations for ARS Pharmaceuticals?
The overall consensus recommendation for ARS Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ARS Pharmaceuticals dividend yield?
ARS Pharmaceuticals does not currently pay a dividend.
Does ARS Pharmaceuticals pay a dividend?
ARS Pharmaceuticals does not currently pay a dividend.
When does ARS Pharmaceuticals next pay dividends?
ARS Pharmaceuticals does not currently pay a dividend.
How do I buy ARS Pharmaceuticals shares?
To buy shares in ARS Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ARS Pharmaceuticals?
As of the previous close price of $7.43, shares in ARS Pharmaceuticals had a market capitalisation of $737.31m.
Where are ARS Pharmaceuticals shares listed?
Here are the trading details for ARS Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SPRY
What kind of share is ARS Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum ARS Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ARS Pharmaceuticals share price forecast for 2026?
The analyst consensus target price for shares in ARS Pharmaceuticals is $26.67. That is 259.19% above the last closing price of $7.43.
Analysts covering ARS Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.59 for the next financial year.
Find out moreWhat is the trend in the ARS Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ARS Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -18.55%.
As of the last closing price of $7.43, shares in ARS Pharmaceuticals were trading -26.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ARS Pharmaceuticals PE Ratio?
The ARS Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ARS Pharmaceuticals?
ARS Pharmaceuticals' management team is headed by:
- Peter Thompson - CHM
- Valerie Odegard - PRE
- Laura Shawver - CEO
- Jonathan Piazza - CFO
- Naomi Hunder - OTH
- Vickie Capps - IND
- Robert Hershberg - IND
- Saqib Islam - IND
- Maria Koehler - IND
- Andrew Powell - IND
- Jonathan Root - IND
- Thilo Schroeder - IND